Can a new CEO fix Novo Nordisk's problems? This analyst says no.

Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down.

BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination with Josh Lipton and Bullseye American Ingenuity Fund portfolio manager Adam Johnson to discuss the surprise C-suite change.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.